Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Operating Leases (2022 - 2026)

Climb Bio filings provide 5 years of Operating Leases readings, the most recent being $216000.0 for Q1 2026.

  • Quarterly Operating Leases fell 32.29% to $216000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $216000.0 through Mar 2026, down 32.29% year-over-year, with the annual reading at $285000.0 for FY2025, 24.0% down from the prior year.
  • Operating Leases hit $216000.0 in Q1 2026 for Climb Bio, down from $285000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $695000.0 in Q2 2022 and bottomed at $15000.0 in Q4 2023.
  • Average Operating Leases over 5 years is $273928.6, with a median of $254000.0 recorded in 2023.
  • The largest annual shift saw Operating Leases tumbled 91.67% in 2023 before it surged 2400.0% in 2024.
  • Climb Bio's Operating Leases stood at $180000.0 in 2022, then tumbled by 91.67% to $15000.0 in 2023, then surged by 2400.0% to $375000.0 in 2024, then decreased by 24.0% to $285000.0 in 2025, then dropped by 24.21% to $216000.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Operating Leases are $216000.0 (Q1 2026), $285000.0 (Q4 2025), and $352000.0 (Q3 2025).